대한의생명과학회지 (Biomedical Science Letters)

  • 제28권4호
  • /
  • Pages.312-316
  • /
  • 2022
  • /
  • 1738-3226(pISSN)
  • /
  • 2288-7415(eISSN)
대한의생명과학회 (The Korean Society for Biomedical Laboratory Sciences)
권호 표지
DOI QR코드

DOI QR Code

Anti-tumor Effect of 4-1BBL Modified Tumor Cells as Preventive and Therapeutic Vaccine

  • Hong Sung, Kim (Department of Biomedical Laboratory Science, Korea Nazarene University)
  • 투고 : 2022.11.01
  • 심사 : 2022.11.28
  • 발행 : 2022.12.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

We have previously reported that genetically modified tumor cells with 4-1BBL have anti-cancer effects in a CT26 mouse colorectal tumor model. In this study, genetically modified tumor cells with 4-1BBL were evaluated for their potential as candidates for preventive and therapeutic cancer vaccine. To identify the effect of preventive and therapeutic vaccine of genetically modified tumor cells with 4-1BBL, tumor growth pattern of CT26-4-1BBL as a cancer vaccine was examined compared to CT26-beta-gal. In therapeutic vaccination, CT26-WT was inoculated into mice and then vaccinated mice with doxorubicin (Dox)-treated CT26-beta-gal and CT26-4-1BBL (single or three times). Triple vaccination with Dox-treated tumor cell inhibited tumor growth compared to single vaccination. Vaccination with CT26-4-1BBL showed an efficient tumor growth inhibition compared to vaccination with CT26-beta-gal. For preventive vaccination, Dox-treated CT26-beta-gal and CT26-4-1BBL was vaccinated into mice with three times and then administered mice with CT26-WT. Preventive vaccination with CT26-4-1BBL showed no tumor growth. Preventive vaccination with CT26-beta-gal also led to tumor-free mice. These results suggest that genetically modified tumor cells with 4-1BBL can be used as therapeutic or preventive cancer vaccine.

키워드

과제정보

This research was supported by Korea Nazarene University Research Fund.

참고문헌

  1. Douin-Echinard V, Bornes S, Rochaix P, Tilkin AF, Peron JM, Bonnet J, et al. The expression of cd70 and cd80 by gene-modified tumor cells induces an antitumor response depending on the mhc status. Cancer Gene Therapy. 2000. 7: 1543-1556. https://doi.org/10.1038/sj/cgt/7700268
  2. Eager R, Nemunaitis J. Gm-csf gene-transduced tumor vaccines. Molecular therapy: the Journal of the American Society of Gene Therapy. 2005. 12: 18-27. https://doi.org/10.1016/j.ymthe.2005.02.012
  3. Hollingsworth RE, Jansen K. Turning the corner on therapeutic cancer vaccines. NPJ Vaccines. 2019. 4: 7.
  4. Jin MZ, Wang XP. Immunogenic cell death-based cancer vaccines. Frontiers in Immunology. 2021. 12: 697964.
  5. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-t immunotherapy for castration-resistant prostate cancer. The New England Journal of Medicine. 2010. 363: 411-422. https://doi.org/10.1056/NEJMoa1001294
  6. Kim HS. Development of genetically modified tumor cell containing costimulatory molecule. Biomed Sci Letters. 2019. 25: 398-406. https://doi.org/10.15616/BSL.2019.25.4.398
  7. Kim HS. CD8-dependent tumor growth inhibition by tumor cells genetically modified with 4-1BBL. Biomed Sci Letters. 2021. 27: 329-333. https://doi.org/10.15616/BSL.2021.27.4.329
  8. Kim SK, Cho SW. The evasion mechanisms of cancer immunity and drug intervention in the tumor microenvironment. Frontiers in Pharmacology. 2022. 13: 868695.
  9. Kooreman NG, Kim Y, de Almeida PE, Termglinchan V, Diecke S, Shao NY, et al. Autologous ipsc-based vaccines elicit antitumor responses in vivo. Cell Stem Cell. 2018. 22: 501-513 e507.
  10. Larocca C, Schlom J. Viral vector-based therapeutic cancer vaccines. Cancer Journal. 2011. 17: 359-371. https://doi.org/10.1097/ppo.0b013e3182325e63
  11. Lipson EJ, Sharfman WH, Chen S, McMiller TL, Pritchard TS, Salas JT, et al. Safety and immunologic correlates of melanoma gvax, a gm-csf secreting allogeneic melanoma cell vaccine administered in the adjuvant setting. Journal of Translational Medicine. 2015. 13: 214.
  12. Lopes A, Vandermeulen G, Preat V. Cancer DNA vaccines: Current preclinical and clinical developments and future perspectives. Journal of Experimental & Clinical Cancer Research. 2019. CR 38: 146.
  13. Munn DH, Bronte V. Immune suppressive mechanisms in the tumor microenvironment. Current Opinion in Immunology. 2016. 39: 1-6. https://doi.org/10.1016/j.coi.2015.10.009
  14. Rosenberg SA. Il-2: The first effective immunotherapy for human cancer. Journal of Immunology. 2014. 192: 5451-5458. https://doi.org/10.4049/jimmunol.1490019
  15. Sadeghi Najafabadi SA, Bolhassani A, Aghasadeghi MR. Tumor cell-based vaccine: An effective strategy for eradication of cancer cells. Immunotherapy. 2022. 14: 639-654. https://doi.org/10.2217/imt-2022-0036
  16. Santos PM, Butterfield LH. Dendritic cell-based cancer vaccines. Journal of Immunology. 2018. 200: 443-449. https://doi.org/10.4049/jimmunol.1701024
  17. Sartoris S, Mazzocco M, Tinelli M, Martini M, Mosna F, Lisi V, et al. Efficacy assessment of interferon-alpha-engineered mesenchymal stromal cells in a mouse plasmacytoma model. Stem Cells and Development. 2011. 20: 709-719.
  18. Schneble E, Clifton GT, Hale DF, Peoples GE. Peptide-based cancer vaccine strategies and clinical results. Methods in Molecular Biology. 2016. 1403: 797-817. https://doi.org/10.1007/978-1-4939-3387-7_46
  19. Srivatsan S, Patel JM, Bozeman EN, Imasuen IE, He S, Daniels D, et al. Allogeneic tumor cell vaccines: The promise and limitations in clinical trials. Human Vaccines & Immuno-therapeutics. 2014. 10: 52-63. https://doi.org/10.4161/hv.26568
  20. Tang T, Huang X, Zhang G, Hong Z, Bai X, Liang T. Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy. Signal Transduction and Targeted Therapy. 2021. 6: 72.
  21. Ullrich E, Bonmort M, Mignot G, Kroemer G, Zitvogel L. Tumor stress, cell death and the ensuing immune response. Cell Death and Differentiation. 2008. 15: 21-28. https://doi.org/10.1038/sj.cdd.4402266
  22. Vinay DS, Ryan EP, Pawelec G, Talib WH, Stagg J, Elkord E, et al. Immune evasion in cancer: Mechanistic basis and therapeutic strategies. Seminars in Cancer Biology. 2015. 35 Suppl: S185-S198. https://doi.org/10.1016/j.semcancer.2015.03.004